Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

March 31, 2026 updated by: M.D. Anderson Cancer Center

Study of Efficacy of Oncology Dashboard in Improving Operational Efficiency and Patient Outcomes

This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVE:

I. To compare the changes in oncology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups.

SECONDARY OBJECTIVES:

I. To compare the changes in radiology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups.

II. Assess and compare the proportion of patients who correctly indicate the changes in tumor size while on therapy at the baseline and at the follow-up visit (with the oncology dashboard tool).

IIa. Compare the change in proportion of patients who correctly indicate the changes in tumor size while on therapy from baseline to follow-up visit between intervention and control groups.

III. Assess the patient's satisfaction with physician communication during the clinic visit and with the current treatment plan at each visit for each group.

IV. Assess changes in the radiology report quality with the following measures (all changes will be compared between intervention and control groups):

IVa. Whether or not the current study was compared to the imaging study that was performed at the start of current therapy.

IVb. The number of time points reviewed by the radiologist. IVc. The time interval between the earliest study reviewed and the current study.

IVd. Percentage of target lesions measured and listed in the radiology report. V. In patients who have stable disease or mildly progressive disease at the time of the baseline assessment, assess the impact of patient understand on the decision to continue and discontinue therapy.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

GROUP II: Patients receive standard of care.

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • M D Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with sarcoma on active chemotherapy/targeted therapy

  • Patients must have stable to mildly progressive disease or better on baseline assessment

    • Baseline measurement and follow-up measurement have to be performed on the same treatment for consistency. If patients with progressive disease are included into the study at baseline, follow-up measurement will be on a different treatment. Invariable, initiation of a new treatment, in the setting of progressive disease, lengthens oncology workflow which would affect the post measurement
  • Patients must have been on the same treatment for at least 6 weeks
  • Patients must have at least 3 prior imaging studies of the same body part/tracked lesion/area of interest separated by 6 weeks or more between studies
  • Patients should be continuing same therapy for the next 6-8 weeks
  • Patients must have plan for follow-up with imaging studies at MD Anderson Cancer Center (MDACC) while on therapy
  • Patients who are receiving therapy outside of MDACC but having their follow-up imaging at MDACC are eligible
  • >= 18 years of age

Exclusion Criteria:

  • Expected survival of less than 8 weeks
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 4
  • Non- English-speaking patients and patients with cognitive impairment who cannot complete the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group I (oncology dashboard)
Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.
Other: Questionnaire Administration
Ancillary studies
Other: Informational Intervention
View oncology dashboard
Experimental: Group II (standard of care)
Patients receive standard of care.
Other: Questionnaire Administration
Ancillary studies
Other: Best Practice
Receive standard of care
Other Names:
  • standard of care
  • standard therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time to complete medical oncology review (oncology workflow)
Time Frame: through study completion, an average of 1 year
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Vinod Ravi, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2015

Primary Completion (Actual)

March 18, 2026

Study Completion (Actual)

March 18, 2026

Study Registration Dates

First Submitted

January 18, 2022

First Submitted That Met QC Criteria

January 18, 2022

First Posted (Actual)

January 31, 2022

Study Record Updates

Last Update Posted (Actual)

April 1, 2026

Last Update Submitted That Met QC Criteria

March 31, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-0707 (Other Identifier: M D Anderson Cancer Center)
  • NCI-2021-09453 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcoma

Clinical Trials on Questionnaire Administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe